04/08/2021at 10:13

Lead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus ahead

Thursday's quarterly report from Novo Nordisk will emphasize the pharmaceutical company's diabetes 2 treatments Ozempic and Rybelsus, as well the new weight-loss drug Wegovy, which is in high demand.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk is looking into a growth-heavy Q2, as it has had tailwind with diabetes 2 drugs Ozempic and Rybelsus, and as the demand is high for its new weight-loss treatment Wegovy.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Eli Lilly specifies guidance for this year's revenue
For subscribers
Anders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: "It's going to be more DIY-based"
For subscribers
Danish scientists raise alarm after discovering link between Bayer drug and brain cancer
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Glenn Saldanha is chairman at the board of Glenmark | Foto: Danish Siddiqui/Reuters/Ritzau Scanpix

Pharma & biotech

Indian generic drugmaker to launch Leo Pharma copycat drug in US

For subscribers

Regulation

EU delays new drug law proposal

For subscribers

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

For subscribers

Initial probes pointed to the contamination coming from the capsules containing Dicillin, or the drug's packaging | Foto: Lægemiddelstyrelsen / Pr

Other

Production at contaminated CMO continues – authorities deny further risks

For subscribers

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

For subscribers

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

The very top of the Danish drugmaker has only grown more distant to its own goal of ensuring 45% male/female representation across leadership teams.

For subscribers

Pharma & biotech

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

One of the Danish drugmaker’s partnered patient organizations did not disclose ties to Novo Nordisk in promotional material for obesity treatment.

For subscribers

Helge Lund, chairman at the board of directors at Novo Nordisk | Foto: Christopher Due Karlsson / Medwatch

Pharma & biotech

Novo Nordisk board discussed supply issues at every meeting in 2022

How to meet surging demand for some of the Danish drugmaker’s most popular drugs was amongst the most debated topics at the year’s board meetings, Chair Helge Lund says.

For subscribers

Lead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus ahead

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Eli Lilly specifies guidance for this year's revenue

Anders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: "It's going to be more DIY-based"

Danish scientists raise alarm after discovering link between Bayer drug and brain cancer

Sign up for our newsletter

Front page now

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Indian generic drugmaker to launch Leo Pharma copycat drug in US

EU delays new drug law proposal

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Production at contaminated CMO continues – authorities deny further risks

Novo Nordisk enters collaboration with AI-driven drug discovery company

Further reading

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

Novo Nordisk board discussed supply issues at every meeting in 2022

Jobs